INTRODUCTION
============

In the decades since the introduction and mainstream uptake of maintenance hemodialysis, outcomes in patients with end-stage kidney disease (ESKD) have improved. Patients on hemodialysis, however, continue to experience much higher rates of mortality than the general population, with particular burdens of cardiovascular disease and cardiovascular death. The nature of cardiovascular disease in uremia is generally recognized to be different from that in patients with normal kidney function, with a high frequency of ventricular remodeling and dysfunction, arrhythmia and sudden cardiac death, and calcific arterial and valve disease \[[@gfy179-B1]\]. Risk factors for cardiovascular disease in ESKD are also different, with contributing factors such as phosphate, inflammatory markers and others. The pathogenesis and the drivers for this accelerated cardiovascular disease process are not completely understood, but the uremic milieu, with retention of numerous solutes normally cleared by the kidney or excreted in the urine, likely plays a large part. In this review, we will examine potential links between the large uremic toxins known as middle molecules and cardiovascular disease, and the gap that exists currently in our ability to remove these molecules.

LARGE UREMIC TOXINS
===================

Hemodialysis effectively removes small water-soluble molecules that circulate without significant protein binding, exemplified by the use of urea clearance as a metric for dialysis dose and kinetic modeling. Molecules that are larger and/or protein-bound are, however, much more difficult to remove. The 'middle molecules', molecules from 500 to 60 000 Da, are a diverse group of molecules, many of which have known toxic effects. Dialysis technologies have been targeted to improve clearance of smaller middle molecules up to ∼15 kDa, such as beta-2 microglobulin, whilst avoiding albumin loss (66 kDa). Modern high-flux membranes are reasonably effective at removing proteins in this lower size range, but clearances are poor for molecules \>15 kDa. Hemodiafiltration (HDF) improves the clearance of molecules up to ∼25 kDa and newer 'medium cut-off' membranes have the potential to more effectively remove larger molecules up to 50 kDa, with limited albumin loss \[[@gfy179-B2]\]. Many of these larger middle molecules are linked directly, or in some cases indirectly, with cardiovascular disease and improved removal of such solutes is a generally accepted goal of improving dialysis technology.

A large number of molecules are known to be retained in uremia, and [Table 1](#gfy179-T1){ref-type="table"} describes 18 that fall into the category of large middle molecules with a size between 15 and 60 kDa, which are cleared poorly by conventional dialysis and for which there is evidence of their involvement in inflammation and or cardiovascular disease. The usual biological role of these molecules is diverse, and they include a number of cytokines, adipokines, growth factors and other signaling proteins. Levels of these proteins can be markedly elevated in uremia, with most cytokines and inflammatory proteins being 2- to 10-fold higher in uremia compared with subjects with normal renal function. Many other middle molecules are \>10-fold higher and some proteins such as fibroblast growth factor (FGF)-23, which is directly involved in phosphate handling can be elevated \>200-fold. Conventional dialysis is universally poor at removing these molecules. Table 1**Middle molecules in the range of 15--60** **kDa that have evidence for involvement in inflammation and cardiovascular disease**Molecule (alternative names)ClassificationMolecular size (kDa)Usual biological roleRelative increase in dialysis or advanced CKDInterleukin-18Cytokine18Pro-inflammatory∼2-fold higherInterleukin-6Cytokine21--28Pro-inflammatory2- to 5-fold higherInterleukin-1βCytokine17.5Pro-inflammatory∼2-fold higherTNF-αCytokine17Pro-inflammatory4- to 5-fold higherSoluble TNF receptor 1 (p75)Protein27--30Limits TNF-α activity3- to 10-fold higherSoluble TNF receptor 2 (p55)Protein17Limits TNF-α activity3- to 10-fold higherPentraxin-3Protein40Opsonization and complement activation. Modulate macrophage activity2- to 7-fold higherYKL-40 (CHI3L1)Protein40Regulates local inflammatory markers. Other functions unclear2- to 5-fold higherAdiponectinAdipokine30Modulates glucose regulation and fatty acid oxidation2- to 3-fold higherVisfatin (NAMPT)Adipokine52Extracellularly stimulates angiogenesis and endothelial cell proliferation3- to 6-fold higherLeptinAdipokine16Regulates appetite and body energy stores3- to 4-fold higherVEGF (vascular permeability factor)Growth factor34Promotes endothelial cell proliferation, migration and differentiation∼2-fold higherFGF-2  (basic fibroblast growth factor)Growth factor18Angiogenic growth factor5- to 20-fold higherFGF-23Growth factor32Regulates phosphate homeostasis\>200-fold higherComplement factor D  (C3 proactivator convertase)Protein24Component of alternative complement pathway; humoral defense4- to 17-fold higherProlactinHormone23Diverse roles2- to 4-fold higherβ-trace protein  (L-prostaglandin D2 synthase)Protein26Catalyzes isomerization of precursor prostanoids to active forms\>35-fold higherAGEsOther\<1--70Unknown2- to 20-fold higher

ROLE OF LARGE MIDDLE MOLECULES IN INFLAMMATION AND CARDIOVASCULAR DISEASE
=========================================================================

There is a strong body of evidence linking inflammation with cardiovascular disease. This relationship has been demonstrated in both the general population and in those with kidney disease. Many of the cytokines and associated inflammatory molecules that are elevated in uremia play a part in this inflammation--cardiovascular disease pathway ([Figure 1](#gfy179-F1){ref-type="fig"}).

![Middle molecules influence multiple steps in atherosclerosis progression. Elevated leptin and AGE levels are associated with endothelial dysfunction, which is also promoted by inflammatory molecules such as PTX3 and IL-1 beta. Elevated cytokines and other molecules such as prolactin and YKL-40 increase leukocyte adhesion and activation leading to foam cell formation. The progression to unstable plaque with migration and proliferation of smooth muscle cells and angiogenesis is also influenced by uremic toxins, eventually leading to plaque rupture and thrombosis.](gfy179f1){#gfy179-F1}

Interleukin 1 beta (IL-1 beta) plays a key stimulatory role in the pro-inflammatory cytokine cascade and has been implicated in the process of atherosclerosis. Animal studies have demonstrated a causative role by examining both genetic or pharmacologic inhibition of IL-1 beta signaling and the progression of atherosclerotic disease \[[@gfy179-B3]\]. In human studies, IL-1 beta is increased in diseased coronary arteries and correlates with plaque severity \[[@gfy179-B4]\]. Gene polymorphism studies also indicate a relationship between interleukin-1 receptor antagonist protein (IL-1-RN) polymorphisms and coronary artery disease suggesting a causative role for IL-1 beta and atherosclerotic disease in humans \[[@gfy179-B5]\]. IL-1 beta has also been associated with left ventricular hypertrophy in dialysis patients \[[@gfy179-B6]\].

IL-18 is also typically elevated in uremia and in human studies, elevated levels have been associated with coronary artery calcification and cardiovascular mortality in chronic kidney disease (CKD) patients \[[@gfy179-B7], [@gfy179-B8]\]. In patients with coronary artery disease, high IL-18 levels are linked to unstable coronary plaque \[[@gfy179-B9]\]. In animal models, IL-18 administration increases plaque formation in susceptible animal models, probably via an interferon (IFN)-gamma-dependent process \[[@gfy179-B10]\].

Elevated levels of IL-6 are also associated with cardiovascular mortality \[[@gfy179-B11]\] and left ventricular hypertrophy \[[@gfy179-B6]\] in patients with CKD and those receiving hemodialysis. IL-6 is believed to play a central role in the development of atherosclerotic lesions, orchestrating the recruitment and ingress of inflammatory cells, as well as having local pro-coagulant effects in the vasculature that promote acute thrombosis \[[@gfy179-B12]\]. The contribution of IL-6 to coronary heart disease is also supported by human Mendelian randomization studies \[[@gfy179-B13]\].

Tumour necrosis factor alpha (TNF-alpha) is a cytokine that is produced by many cell types in response to inflammatory stimuli and also downstream of other cytokines such as IL-1. It has potent effects upregulating the immune response and produces a wide range of systemic effects including the suppression of appetite and induction of fever. TNF-alpha is typically elevated 4- to 5-fold in patients with ESKD and is associated with left ventricular hypertrophy in patients receiving dialysis \[[@gfy179-B6]\]. High levels of circulating TNF-alpha are thought to contribute to myocardial dysfunction and fibrosis, as well as influencing vascular disease via multiple pathways, such as increasing coagulation activators, destabilizing endothelial structure and promoting proliferation and migration of vascular smooth muscle cells \[[@gfy179-B14]\]. Intervention studies in humans demonstrated acute adverse vascular effects from TNF-alpha infusion and TNF-alpha is thus thought to contribute to the early development stages of atherosclerosis \[[@gfy179-B15]\]. In ESKD, the soluble TNF receptors 1 and 2 (27 kDa and 17 kDa) are both also elevated significantly and may limit TNF-alpha activity in the acute setting. However, they also act to prolong the activity and half-life of circulating TNF-alpha, thus potentially contributing to the chronic inflammatory state and consequent cardiovascular disease.

Pentraxin-3 (PTX3), a 40-kDa member of the family of acute phase reactant pentraxins which include also C reactive protein (CRP), is considered to be part of the 'long pentraxin' subfamily. It is rapidly secreted primarily, but not exclusively, by leukocytes when stimulated by pro-inflammatory cytokines such as TNF-alpha and IL-1, or by other activators of the innate immune system, and has general functions including binding to pathogens for opsonization and complement activation. PTX3, similar to the prototypical short pentraxin CRP, has been observationally linked to increased risk of cardiovascular death and mortality in a number of studies, some including patients with CKD \[[@gfy179-B16]\]. PTX3 may be a more specific marker than CRP for atherosclerosis however, as it is produced abundantly by cells within atherosclerotic lesions rather than by the liver, as is CRP. Several studies have linked PTX3 with unstable plaque in coronary and carotid arteries \[[@gfy179-B17], [@gfy179-B18]\]. It is not entirely clear, however, if PTX3 has a primary causative role in atherosclerosis, though PTX3 does have pro-thrombotic effects by interfering with nitric oxide (NO) production and augmenting the local expression of tissue factor in response to stimuli \[[@gfy179-B19]\]. PTX3 can also be generated in vascular smooth muscle cells in response to atherogenic lipids, suggesting a possible place in the pathway of atherosclerosis progression \[[@gfy179-B20]\].

ADIPOKINE DERANGEMENT IN UREMIA AND CARDIOVASCULAR DISEASE
==========================================================

Cell signaling proteins secreted by adipose tissue overlap in part with cytokines, but a number of these proteins secreted almost exclusively by adipose tissue have been termed adipokines. These molecules have a variety of roles and several are in the middle molecule size range and accumulate in kidney disease. These include adiponectin, which is exclusively generated by adipose tissue. Serum concentrations of adiponectin are in general inversely correlated with body fat quantities. Adiponectin circulates as trimers or larger conglomerates and the higher molecular weight forms are thought to be more biologically active with a protective role. Low adiponectin levels have been implicated in obesity-related insulin resistance, the metabolic syndrome and cardiovascular disease \[[@gfy179-B21]\]. Although adiponectin is elevated in uremia, the relationship appears to be modified by amounts of fat mass and inflammation \[[@gfy179-B22]\].

Adiponectin has variable relationships with atherosclerosis development in studies, possibly due to the variety of molecular sizes at which it exists, which may have different actions on different receptors. Most studies support an anti-inflammatory role, though whether this is true in CKD where generally high adiponectin levels coexist paradoxically with a high risk of cardiovascular disease is still unclear. Elevated adiponectin is associated with an increased risk for death in renal transplant recipients \[[@gfy179-B23]\], and correlated with inflammatory cytokines such as IL-6 and TNF-alpha in dialysis population \[[@gfy179-B24]\]. Other studies have found a U-shaped association between mortality and adiponectin \[[@gfy179-B22]\], suggesting possible confounding by malnutrition and inflammation/wasting.

In contrast to adipokine, leptin has a clearer role in atherosclerosis, contributing to early-stage atheroma formation by impairing vasorelaxation via increasing endothelin and causing dysregulation of NO production \[[@gfy179-B25]\]. Furthermore, leptin appears to potentiate Angiotensin II-related vascular dysfunction via increasing the expression of type-1 Angiotensin II receptors in vascular smooth muscle cells as well as promoting hypertrophy of these cells \[[@gfy179-B26]\]. Leptin also increases local expression of inflammatory cytokines thus promoting inflammation-related damage \[[@gfy179-B27]\]. In addition, leptin also enhances platelet activation leading to thrombus formation. Studies have demonstrated that high levels of circulating leptin are an independent risk factor for acute cardiovascular events \[[@gfy179-B28]\].

Visfatin, also known as nicotinamide phosphoribosyltransferase (NAMPT) or historically as pre-B cell colony-enhancing factor, is an adipokine primarily but not exclusively secreted by visceral adipose tissue. At 52 kDa, it is one of the largest middle molecules to be elevated in uremia \[[@gfy179-B29]\]. Intracellularly, it is involved in nicotinamide adenine dinucleotide biosynthesis but it is also released extracellularly, where it appears to have a wide range of effects including stimulating angiogenesis and endothelial cell proliferation. It also promotes the growth of vascular smooth muscle cells, has anti-apoptotic effects on macrophages and promotes vascular inflammation and endothelial damage \[[@gfy179-B30]\]. High levels of visfatin expression have been found in atherosclerotic plaque in human studies. Furthermore, circulating levels of visfatin predict the presence of unstable plaque \[[@gfy179-B31]\].

OTHER LARGE UREMIC TOXINS LINKED WITH CARDIOVASCULAR DISEASE
============================================================

YKL-40, also known as chitinase-3-like protein 1 (CHI3L1), has a molecular weight of 40 kDa. It has precise role in inflammation and angiogenesis though its preciseness is unclear. It is secreted by activated macrophages and other cells and is induced by pro-inflammatory cytokines. YKL-40 is known to regulate other inflammatory markers, such as increasing the expression of monocyte chemoattractant protein-1 and activating cytoplasmic signaling pathways that increase cell proliferation and survival. Circulating YKL-40 levels have been observationally associated with stroke risk \[[@gfy179-B32]\], and a possible causative role is supported by associations also with homozygosity for a single-nucleotide polymorphism in the *CHI3L* gene (which relates to YKL-40) \[[@gfy179-B32]\]. In dialysis patients, YKL-40 correlates with the presence of known coronary artery disease, though studies in other populations do not support a clear link with coronary disease \[[@gfy179-B33]\]. The study of YKL-40 has not yet progressed to delineate a clear mechanistic link with disease but given the appearance as a stroke marker this deserves further exploration.

The family of growth factors contains many arms that are involved broadly in stimulating proliferation and cellular differentiation, and several are increased in uremia, including vascular endothelial growth factor (VEGF) (elevated ∼2-fold), FGF-2 (elevated ∼5- to 20-fold) and FGF-23 (∼200-fold higher). The 34 kDa molecule VEGF is an essential regulator of angiogenesis both in normal physiology and in disease states such as cancer. VEGF promotes endothelial cell proliferation, migration and differentiation in endothelial cells and elsewhere. VEGF also appears to have an important role in cardiac adaptation to hypoxia and stretch, being upregulated by these stimuli and notably increased in cardiac hypertrophy \[[@gfy179-B34]\]. VEGF expression is present in atherosclerotic plaque in human subjects and correlates with CKD grade in this setting \[[@gfy179-B35]\].

FGF-2 is a signaling protein that is closely linked with the process of cardiac hypertrophy, providing paracrine mediation between cardiac fibroblasts and cardiomyocytes. In knockout mouse models, the lack of FGF-2 prevents compensatory hypertrophy in angiotensin II-dependent hypertension \[[@gfy179-B36]\] and this has also been demonstrated in pressure/volume overload models, which are likely applicable to ESKD \[[@gfy179-B37]\]. Interestingly, circulating FGF-2 has an inverse relationship with atheroma progression in CKD patients suggesting both deleterious and beneficial roles in cardiac disease \[[@gfy179-B38]\]. FGF-23 has also been demonstrated to directly cause left ventricular hypertrophy when administered in animal models \[[@gfy179-B39]\], and this can be attenuated with a FGF-23 blocker. Furthermore, FGF-23 levels correlate closely with Left Ventricular Hypertrophy in human observational studies \[[@gfy179-B40]\], and this extends to patients with CKD \[[@gfy179-B39]\].

Complement factor D is an integral component of the alternative complement pathway, being the rate-limiting step in the production of C3 convertase. It is elevated significantly (4- to 17-fold) in ESKD, and thus contributes to dysregulation of the complement system in these patients, priming them for excessive complement activation. Complement activation and deposition is known to play a role in endothelial dysfunction and cardiac ischemia-reperfusion injury. In animal models, blockade of complement components has been demonstrated to reduce tissue injury in this setting \[[@gfy179-B41]\].

Prolactin levels in CKD are high due to reduced renal clearance and increased production. Prolactin is now recognized to have diverse roles, some of which are involved in cardiovascular disease at different levels. At the endothelial level, prolactin stimulates the adhesion of mononuclear cells to endothelial cells in response to inflammatory cytokines \[[@gfy179-B42]\]. The main 23 kDa fragment is a driver of angiogenesis \[[@gfy179-B43]\]. Excess prolactin in the setting of prolactinoma is also associated with impaired insulin sensitivity and adverse effects on lipids \[[@gfy179-B44]\]. A role for prolactin in cardiovascular disease is supported by the association between prolactinoma and an elevated risk for incident cardiovascular disease in males compared with control subjects \[[@gfy179-B45]\] and in CKD patients, prolactin levels have been positively associated with mortality and cardiovascular death \[[@gfy179-B46]\].

Beta-trace protein is normally freely filtered and metabolized completely by the renal tubule, and it is usually elevated 20- to 30-fold in ESKD. Functionally it is involved in prostanoid synthesis and is heavily expressed in the heart and cardiac vessels. Beta-trace protein levels correlated strongly with cardiovascular disease and atheroma in hemodialysis patients \[[@gfy179-B47]\], and prostaglandins from the pathway catalyzed by beta-trace protein have many cardiovascular effects. These are thought, however, to be cardioprotective with anti-thrombotic and anti-atherogenic potential \[[@gfy179-B48]\], and in animal models gene knockout also causes accelerated atherosclerosis \[[@gfy179-B49]\].

Advanced glycosylation end products (AGEs) refer to a large group of different molecules that result from the nonenzymatic glycation of proteins and lipids, and can be endogenously generated or from dietary sources, though the latter appears not to contribute to the high levels that accumulate in uremia \[[@gfy179-B50]\]. They exist in a variety of sizes although in the hemodialysis population the main fractions are found at ∼70, ∼14 and \<2 kDa \[[@gfy179-B51]\]. AGE levels predict cardiovascular mortality in the dialysis population \[[@gfy179-B52]\] and are thought to contribute structurally to vascular disease and inflammation \[[@gfy179-B53]\]. The receptors for AGEs may also be involved in endothelial dysfunction in dialysis patients by enhancing adhesion molecule expression and interfering with NO synthesis in blood vessels \[[@gfy179-B50]\].

CURRENT AND FUTURE STRATEGIES TO REMOVE LARGE MIDDLE MOLECULES
==============================================================

Conventional hemodialysis with high-flux membranes has very limited clearance of larger middle molecules, e.g. clearance of 1.8 mL/min for complement factor D (24 kDa) compared with 208 mL/min for urea \[[@gfy179-B54]\]. Therapies utilizing convection such as HDF are one such strategy that has been promoted to improve clearance of middle molecules. Studies comparing low-flux hemodialysis and HDF have demonstrated better beta-2 microglobulin (\<15 kDa) clearance with HDF \[[@gfy179-B55]\] but comparisons between HDF and HD using high-flux membranes have been less impressive \[[@gfy179-B56]\], and clearance of larger middle molecules is severely limited due to membrane pore size. Membranes with larger pores ('high cut-off' dialyzers) have been developed with initial interest primarily in use for acute kidney injury secondary to acute load of large middle molecules such as free light chains in myeloma \[[@gfy179-B57]\]. The use of such membranes, however, results in a large amount of albumin loss along with the removal of the target proteins. Improvements in manufacturing technology have now allowed improvements in the uniformity of pore distribution, enabling the production of membranes that will allow greater clearance of larger molecules but without significant albumin loss (medium cut-off membranes). Studies to date show that these membranes improve clearance of larger molecules significantly compared with high-flux dialysis. For example, clearance of complement factor D (24 kDa) was improved from 1.8 mL/min to 26--35 mL/min using medium cut-off membranes compared with high flux, and the reduction ratio for YKL-40 (40 kDa) similarly increased from 19% to 61--71% \[[@gfy179-B54]\]. This technology offers a leap in our ability to remove these large uremic toxins, and studies are now required to define the medium- and long-term safety of this approach as well as patient outcome data.

CONCLUSIONS
===========

Large middle molecules are a diverse group of uremic toxins that contribute significantly to the high cardiovascular disease burden in ESKD. Dialysis technologies available to date offer limited clearance of these molecules. A new generation of membranes demonstrates improved clearance and now need to be tested prospectively to determine if improved clearance will lead to improved patient outcomes.
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